Pancreatic head cancer accounts for about 80 percent of pancreatic cancers
“The king of cancer” pancreatic cancer is a common clinical malignant tumor, among which pancreatic head cancer accounts for about 80% of pancreatic cancer.Although pancreatic cancer is less common than other gastrointestinal tumors, accounting for about 2% to 3% of all malignancies, it has a very high mortality rate, with a 5-year survival rate of less than 7%.The pancreas is located in the deepest part of the upper abdomen, and is surrounded by abundant blood vessels and nerves. However, most pancreatic cancer cells have a high degree of malignancy, which is easy to invade the surrounding lymph nodes and blood vessels, resulting in metastasis and diffusion of cancer cells, which rapidly spread to all organs and tissues of the body, increasing the difficulty of treatment.R0 resection is still the only cure, but the resection rate of pancreatic cancer is only 15%-20% due to the low early diagnosis rate and low drug efficiency.In the absence of metastasis, the main reasons affecting the operation are tumor infiltration and vascular invasion, and up to 30% to 40% of the patients give up the resection due to vascular involvement. If the arterial wrapping operation is very difficult and the incidence of postoperative complications is high, the operation is generally not recommended.Neoadjuvant chemotherapy is the first choice for patients with pancreatic head cancer complicated with vascular invasion. On the one hand, neoadjuvant therapy can shrink the tumor of patients, and on the other hand, tumor and vascular separation can be achieved through tumor shrinkage to improve the probability of surgery.But in many cases, the effectiveness of drugs is not high, reducing the chances of surgery.